CLOV vs JNJ: fair value comparison
Clover Health Investments, Corp. and Johnson & Johnson · Updated 2026-10-19
CLOV's estimate rests on a sector-average multiple, which TickrTrends does not publish as a verdict. Within Healthcare, CLOV currently ranks higher by quality score.
| CLOV | JNJ | |
|---|---|---|
| Verdict | Awaiting full valuation | Overvalued |
| Last price | $4.48 | $261.44 |
| 12-month range | $1.70–$5.41 | $186.00–$278.43 |
| Rank by discount to fair value | — | #87 of 108 Healthcare |
| Rank by quality score | #148 of 301 Healthcare | #149 of 301 Healthcare |
| Quality grade | D | D |
| Leverage | — | Low |
| Margin trend | Contracting | Stable |
| Revenue growth | High | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | — |
| 52-week position | The upper-middle quarter | The top quarter |
Full single-stock breakdowns: CLOV fair value analysis · JNJ fair value analysis